Core Insights - The Beijing Stock Exchange (BSE) is becoming a significant platform for innovative small and medium-sized enterprises, with 290 listed companies and a total market capitalization nearing 1 trillion yuan as of January 23, 2026 [1][4] Group 1: Recent Listings - Three companies have recently gone public on the BSE: Kema Materials, Aisheren, and Guoliang New Materials, all of which have shown strong stock performance post-listing [2][3] - Kema Materials, specializing in dry and wet friction plates, saw its stock price surge by 371.27% on its first trading day, closing at 54.95 yuan per share [2] - Aisheren, focused on medical health products, experienced a 175.59% increase in its stock price, closing at 44.04 yuan per share on its debut [2] - Guoliang New Materials, a leader in refractory materials, had a first-day stock price increase of 160.78%, closing at 28.06 yuan per share [3] Group 2: Investor Participation - Investor enthusiasm for new stock offerings remains high, with over 800 billion yuan frozen for the three new listings, resulting in low allocation rates of 0.02%-0.03% [4] - Kema Materials attracted 855.76 billion yuan in frozen funds with a subscription rate of 0.026%, while Aisheren had 878.92 billion yuan with a rate of 0.028%, and Guoliang New Materials saw 828.08 billion yuan with a rate of 0.021% [4] - The upcoming IPOs of Nongda Technology and Medela are expected to draw significant investment, with Nongda Technology's recent offering seeing 9.29 billion yuan frozen and a subscription multiple of 2582.89 times [4] Group 3: Regulatory Environment - The frequency of IPO review meetings at the BSE has significantly increased since Q4 2025, focusing on nurturing specialized and innovative hard-tech enterprises [4] - In the week of January 19-23, the BSE's listing committee held three review meetings, successfully approving three companies: Bairuiji, Mifutech, and Toptech [4] - The enhanced review efficiency and improved market ecology position the BSE as a core channel for innovative enterprises to connect with capital markets [4]

截至2026年1月23日收盘，拱东医疗(605369)报收于19.65元，下跌0.1%，换手率0.57%，成交量1.26万 手，成交额2482.22万元。 当日关注点 交易信息汇总资金流向 1月23日主力资金净流出89.96万元，占总成交额3.62%；游资资金净流出27.77万元，占总成交额 1.12%；散户资金净流入117.72万元，占总成交额4.74%。 来自交易信息汇总：1月23日主力资金净流出89.96万元，占总成交额3.62%。 来自业绩披露要点：拱东医疗预计2025年全年归属净利润盈利4400万元至5600万元。 来自公司公告汇总：拱东医疗预计2025年度扣除非经常性损益后的净利润同比减少60.75%到 67.89%，主要受商誉减值、毛利率下降及汇率波动等因素影响。 业绩披露要点业绩预告 拱东医疗发布业绩预告，预计2025年全年归属净利润盈利4400万元至5600万元；扣非后净利润盈利5400 万元至6600万元。 公司公告汇总拱东医疗：2025年年度业绩预告 浙江拱东医疗器械股份有限公司预计2025年度实现归属于母公司所有者的净利润为4,400.00万元到 5,600.00万元，同比减少67.3 ...

Core Viewpoint - The Nanjing Market Supervision Administration organized a training session to enhance the intellectual property protection capabilities of local medical device companies as they expand into international markets [1][2] Group 1: Training Session Details - The training involved over 20 representatives from listed and key export medical device companies, as well as personnel from intellectual property law firms and service organizations [1] - The format included on-site observation, specialized lectures, and interactive Q&A sessions to help companies identify key issues in overseas intellectual property protection [1] - Experts provided insights on constructing overseas trademark brand strategies and patent risk prevention for medical device companies [1] Group 2: Expert Contributions - Experts Cao Yingjie and Zhang Rui discussed strategies and methods for foreign intellectual property protection during the specialized training sessions [1] - The Q&A segment addressed specific concerns from company representatives regarding trademark and patent layout, international market expansion, and infringement dispute responses [1] Group 3: Future Initiatives - The Nanjing Market Supervision Administration plans to continue optimizing training formats and content to support the innovative and international development of the medical device industry [2]

Group 1 - The core viewpoint of the article highlights that Furui Medical (300049) has released its earnings forecast for 2025, projecting a significant increase in net profit [1][3] - On January 23, 2026, Furui Medical's stock closed at 73.2 yuan, with a slight increase of 0.87% and a trading volume of 65,000 shares, amounting to a transaction value of 479 million yuan [1] - The company anticipates a net profit attributable to shareholders ranging from 135 million yuan to 164 million yuan for 2025, representing a year-on-year growth of 19.17% to 44.77% [1][3] Group 2 - The earnings forecast indicates that the net profit after deducting non-recurring gains and losses is expected to be between 127 million yuan and 166 million yuan, reflecting a growth of 7.89% to 41.02% year-on-year [1] - The growth in earnings is primarily driven by the increase in revenue and profit from the medical device business of its French subsidiary, along with stable contributions from the company's managed medical strategy in pharmaceuticals and medical services [1][3] - The net inflow of main funds on January 23 was 4.0411 million yuan, while retail investors experienced a net outflow of 7.9863 million yuan [1][3]

Core Insights - The company, Shenzhen Beixin Life Technology Co., Ltd., has successfully completed its initial public offering and is now listed on the Sci-Tech Innovation Board, marking a significant milestone in its growth journey [2] - The company focuses on innovative and high-quality solutions for cardiovascular disease treatment, emphasizing its commitment to clinical and patient-centered approaches [2] Product Development - The core products, including the Intravascular Ultrasound (IVUS) system and the Fractional Flow Reserve (FFR) system, have entered the national special review process for innovative medical devices, which is expected to transform clinical practices in Percutaneous Coronary Intervention (PCI) [3] - The Pulsed Field Ablation (PFA) system for atrial fibrillation treatment is also in the special review process and is the first PFA product from China to be included in the late-breaking clinical trial at the European Society of Cardiology Congress [3] - The InsightPFA clinical research results have been published in the top cardiovascular journal, JACC, representing the first randomized controlled clinical study of nanosecond pulse PFA in the industry [3] Future Outlook - The medical device sector is entering a new cycle of innovation characterized by intelligence and precision, presenting a historic strategic opportunity for Chinese medical enterprises to develop into globally influential medical technology companies over the next decade [4] - The company aims to leverage the "Healthy China" strategy, maintaining its focus on cardiovascular precision intervention and striving for exceptional quality, thereby showcasing the strength of Chinese innovation to the world [4] - The company expresses a desire for investors to understand its value proposition and growth potential, highlighting the opportunity for shared long-term growth [4]

本次上市是公司迈向新阶段的关键一步，也是北芯生命实现愿景的战略机遇。我们将以此为契机，充分 把握全球医疗器械行业向智能化、精准化加速迭代的黄金增长期，加大研发投入，继续推进在心血管智 能化精准介入领域的创新突破，并在海内外市场进一步扩大影响力。 感谢各位投资者对我们的期待，我们将始终牢记这份责任，严格遵照相关法律法规要求，确保信息披露 的准确性与透明度。未来，我们将继续与各位投资者保持紧密联系，分享公司的发展成果，在改善生命 健康的航程中，共同实现患者关爱和长期价值创造。我们期待与大家携手，创造和分享属于北芯生命更 加美好的未来，并以更加优良的业绩回报股东、回报投资者、回报社会。谢谢大家！ 深圳北芯生命科技股份有限公司首次公开发行股票并在科创板上市网上投资者交流会已接近尾声。在 此，我谨代表北芯生命，感谢大家对本次发行的热情关注和踊跃提问。也十分感谢上证路演中心、上海 证券报以及中国证券网为我们提供了良好的沟通平台和优质服务。同时，衷心感谢保荐机构中金公司及 所有中介机构为公司发行上市所做出的努力。 通过今天的网上投资者交流活动，我们对北芯生命的主营业务、经营业绩、竞争优势、募投项目、发展 战略及长期价值向大 ...

Group 1 - The core viewpoint is that Beixin Life has rapidly become a leader in China's medical device industry, focusing on cardiovascular precision intervention with innovative products [2] - Beixin Life's core products, the intravascular ultrasound (IVUS) diagnostic system and the fractional flow reserve (FFR) measurement system, have entered the national special review procedure for innovative medical devices [2] - The company is the first domestic medical device company to have a combination of intravascular functional FFR and imaging IVUS products, filling a gap in the domestic market and changing the reliance on imported products for clinical precision diagnosis of coronary artery disease in China [2] Group 2 - The underwriting and lead underwriting of Beixin Life's IPO is handled by China International Capital Corporation (CICC), which has witnessed the company's steady and rapid development and recognizes the management's industry insight and experience [2] - The company's technology platform, R&D system, and rich product pipeline lay a solid foundation for long-term development [2] - The IPO will inject more capital into Beixin Life, further promoting the industrialization of its core products and strengthening its global market layout [2]

Core Viewpoint - The company focuses on innovative medical devices for precise cardiovascular diagnosis and treatment, aiming to improve health outcomes through quality and innovation [1] Business Overview - The company specializes in the research, development, production, and sales of innovative medical devices for cardiovascular diseases, addressing clinical needs in areas such as coronary artery disease, peripheral vascular disease, and atrial fibrillation [1] - As of September 30, 2025, the company has launched 11 products and has 6 products in development, covering five major categories including IVUS systems and FFR systems [2] Operational Performance - The core product, the FFR system, captured 30.6% of the domestic market share in 2021, with over 70% of its usage in tertiary hospitals across 30 provinces in China and clinical applications in over 1,000 hospitals globally [3] - The IVUS system is the first domestically developed 60MHz high-definition product approved by the National Medical Products Administration, achieving a market share of 10.4% in the coronary disease sector by 2024 [3] Research and Development - The company has established four core technology platforms to support continuous innovation in cardiovascular medical devices, resulting in 25 Class III medical device registrations and 185 patents as of June 30, 2025 [4] - The R&D team consists of 100 members, with over 40% holding advanced degrees, ensuring a strong foundation for long-term development [9] Financial Performance - The company's revenue for the periods from 2022 to 2025 is projected to grow significantly, with expected net profits for 2025 ranging from 78 million to 88 million yuan, representing a growth of 278.91% to 301.85% year-on-year [6] - The gross profit margins for the same periods are reported at 63.50%, 65.02%, 63.32%, and 69.06%, indicating stable margins due to increased production scale [7] Industry Context - The cardiovascular disease market in China is rapidly growing, with PCI procedures being the main application for the company's products, although the penetration rate remains lower than in developed countries [12] - Future trends indicate an increase in PCI penetration, a shift towards high-end active intervention devices, and a growing emphasis on integrated diagnostic solutions [13] Competitive Advantages - The company emphasizes its focus on precise cardiovascular solutions, strong independent R&D capabilities, and a well-established commercialization network, positioning itself favorably in the market [11] Funding and Investment - The company plans to raise approximately 952.21 million yuan through its public offering, with funds allocated for the construction of a medical device industrialization base and R&D projects [19][20][21]

截至2026年1月23日收盘，振德医疗(603301)报收于70.94元，上涨1.74%，换手率0.88%，成交量2.33万 手，成交额1.64亿元。 当日关注点 交易信息汇总 来自交易信息汇总：1月23日主力资金净流出618.19万元，占总成交额3.77%。 来自公司公告汇总：振德医疗拟回购并注销第二期员工持股计划未解锁股份合计1,829,868股，同 时变更回购股份用途并注销其他股份，总计注销1,959,310股。 来自股本股东变化：公司总股本拟由265,835,535股减少至263,876,225股，注册资本相应减少。 公司公告汇总 振德医疗第四届董事会第六次会议审议通过《公司第二期员工持股计划（草案修订稿）》及其摘要、 《公司第二期员工持股计划管理办法（修订稿）》、回购第二期员工持股计划未解锁股份1,829,868股 （回购价格22.17元/股）、变更回购股份用途并注销共计1,959,310股股份、变更公司注册资本及修改公 司章程等议案，相关事项尚需提交股东会审议。 公司将于2026年2月9日召开2026年第二次临时股东会，股权登记日为2026年2月2日，会议将采用现场投 票与网络投票相结合方式审议上 ...

Core Viewpoint - The National Medical Insurance Administration has released a guideline to standardize pricing for surgical robots and other advanced medical technologies, aiming to facilitate the clinical application of innovative medical technologies and promote a shift towards precision medicine [3][4]. Group 1: Pricing Guidelines - The guideline establishes 37 pricing items, including 5 additional charges and 1 expansion item, covering key technologies such as 3D printing, imaging enhancement, energy devices, intraoperative guidance, surgical robots, and remote surgery [3]. - The pricing framework focuses on the clinical value of new technologies rather than the equipment or surgical site, allowing for a more equitable and transparent pricing model [6][22]. - The guideline introduces a tiered pricing system based on the level of participation and precision of surgical robots, encouraging their use in complex surgeries while preventing misuse in low-value scenarios [6][25]. Group 2: Impact on Remote Surgery - The guideline includes a separate pricing item for remote surgery, facilitating its transition from exploration to practical application [7]. - Remote surgery is particularly significant in emergency situations, such as cardiovascular diseases, where timely intervention is critical [8]. - The establishment of a payment framework for remote surgery is expected to enhance access to quality medical resources across regions, benefiting patients significantly [10][21]. Group 3: Encouragement of Innovation - The release of the guideline signals a clear intent from the government to incentivize continuous innovation in the high-end medical equipment sector [11][12]. - Companies are expected to gain confidence in investing in research and development due to the stable policy environment created by the guideline [12]. - The guideline aims to create a commercial logic loop that supports the sustainable development of innovative medical technologies [11][14]. Group 4: Market Dynamics - The market for surgical robots in China is expected to grow significantly, with domestic market share projected to increase from 32.61% in 2023 to 48.89% in 2024 [17]. - Despite the growth, the overall penetration of robotic surgeries remains low compared to countries like the United States, indicating substantial room for expansion [17]. - The establishment of a unified payment framework is anticipated to activate the existing market for surgical robots, leading to potential growth for companies already holding market share [17]. Group 5: Balancing Costs and Innovation - The guideline aims to balance the need for high-level innovation with the financial burden on patients by establishing pricing boundaries [22][25]. - It specifies that devices with multiple functionalities will be charged based on the highest service price, ensuring fair compensation for advanced capabilities [23][24]. - The National Medical Insurance Administration will guide local agencies in setting reasonable pricing standards, reflecting the value of technical services [26][27].